Cue Biopharma, Inc. Appoints Randall R. Rader to Serve as the Chair of Intellectual Property Committee
October 03, 2018 at 09:00 am EDT
Share
Cue Biopharma, Inc. announced that Randall R. Rader has agreed to serve as the Chair of the company's Intellectual Property Committee. For twenty-six years (1988 to 2014), Judge Rader served as a United States Federal trial and appellate judge. During that time, he served as a judge on the United States Court of Appeals for the Federal Circuit from 1994 to 2014, including presiding as Chief Judge from 2010 to 2014. Throughout his tenure, Judge Rader authored pivotal decisions in nearly every area of patent and trademark law. He also conducted jury trials as a District Court Judge sitting by designation in California, New York, Texas and Illinois. Prior to entering the Federal Judiciary, Judge Rader served as the Chief Counsel (Majority and Minority) to the Senate Judiciary Committee Subcommittees, where he contributed to important intellectual property legislation including the Bayh-Dole Act, the Hatch-Waxman Act, the Berne Convention Implementation Act, and the Federal Courts Improvement Act.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
CUE BIOPHARMA, INC. 
